Literature DB >> 11685500

Peptide radiopharmaceuticals for diagnosis and therapy.

A Signore1, A Annovazzi, M Chianelli, F Corsetti, C Van de Wiele, R N Watherhouse.   

Abstract

Radiolabelled peptides are an emerging class of radiopharmaceuticals that share chemical and biological properties. From the chemical point of view they have a poly-amino acid structure varying from 3 to more that 200 amino acids, and they are labelled with different isotopes directly or by a linker. Biologically, they bind to specific cell membrane receptors, thus providing in vivo histopathological information for diagnostic purposes, therapy follow-up or targeted radiotherapy. This paper reviews most of the radiolabelled peptides that have been tested in animals and humans in the fields of oncology, neurology, cardiology, inflammation/infection, atherosclerosis and thrombosis. A new classification is also proposed for peptides targeting tumour cells based on the biological function of target receptors. These tailored radiopharmaceuticals are the basis of the new era of "molecular nuclear medicine".

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11685500     DOI: 10.1007/s002590100583

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  16 in total

1.  Molecular imaging in oncology by means of nuclear medicine: fact or fiction?

Authors:  Christophe Van de Wiele
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-02       Impact factor: 9.236

Review 2.  Bifunctional coupling agents for radiolabeling of biomolecules and target-specific delivery of metallic radionuclides.

Authors:  Shuang Liu
Journal:  Adv Drug Deliv Rev       Date:  2008-04-23       Impact factor: 15.470

Review 3.  Nuclear imaging of molecular processes in cancer.

Authors:  Rafael Torres Martin de Rosales; Erik Arstad; Philip J Blower
Journal:  Target Oncol       Date:  2009-09-25       Impact factor: 4.493

Review 4.  Protein scaffold-based molecular probes for cancer molecular imaging.

Authors:  Zheng Miao; Jelena Levi; Zhen Cheng
Journal:  Amino Acids       Date:  2010-02-21       Impact factor: 3.520

5.  In vitro and in vivo evaluation of ⁶⁴Cu-radiolabeled KCCYSL peptides for targeting epidermal growth factor receptor-2 in breast carcinomas.

Authors:  Senthil R Kumar; Fabio A Gallazzi; Riccardo Ferdani; Carolyn J Anderson; Thomas P Quinn; Susan L Deutscher
Journal:  Cancer Biother Radiopharm       Date:  2010-12       Impact factor: 3.099

Review 6.  pH-sensitive membrane peptides (pHLIPs) as a novel class of delivery agents.

Authors:  Oleg A Andreev; Donald M Engelman; Yana K Reshetnyak
Journal:  Mol Membr Biol       Date:  2010-10-13       Impact factor: 2.857

7.  Clinical feasibility of two-step streptavidin/111In-biotin scintigraphy in patients with suspected vertebral osteomyelitis.

Authors:  Elena Lazzeri; Ernest K J Pauwels; Paola A Erba; Duccio Volterrani; Mario Manca; Lisa Bodei; Donatella Trippi; Antonio Bottoni; Renza Cristofani; Vincenzo Consoli; Christopher J Palestro; Giuliano Mariani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-07-06       Impact factor: 9.236

Review 8.  Molecular imaging in atherosclerosis.

Authors:  Andor W J M Glaudemans; Riemer H J A Slart; Alessandro Bozzao; Elena Bonanno; Marcello Arca; Rudi A J O Dierckx; Alberto Signore
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-03-20       Impact factor: 9.236

9.  Improved kinetic stability of DTPA- dGlu as compared with conventional monofunctional DTPA in chelating indium and yttrium: preclinical and initial clinical evaluation of radiometal labelled minigastrin derivatives.

Authors:  Martin Béhé; Wolfgang Becker; Martin Gotthardt; Christa Angerstein; Thomas M Behr
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05-24       Impact factor: 9.236

10.  [64Cu-NOTA-8-Aoc-BBN(7-14)NH2] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues.

Authors:  Adam F Prasanphanich; Prasant K Nanda; Tammy L Rold; Lixin Ma; Michael R Lewis; Jered C Garrison; Timothy J Hoffman; Gary L Sieckman; Said D Figueroa; Charles J Smith
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-12       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.